Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study-Reference-Cited by-同舟云学术

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study

Published:2022-10 Issue: Volume:172 Page:154-159
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Addeo Alfredo,Rothschild Sacha I.,Holer Lisa,Schneider Martina,Waibel Christine,Haefliger Simon,Mark Michael,Fernandez Eugenio,Mach Nicolas,Mauti Laetitia,Jermann Philip M.,Alborelli Ilaria,Calgua Byron,Savic-Prince Spasenija,Joerger Markus,Früh Martin

Funder

Bayer HealthCare Pharmaceuticals Inc

Krebsliga Schweiz

Bayer

Staatssekretariat für Bildung, Forschung und Innovation

Swiss Cancer Research Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application;Chae;Oncotarget,2017